PAH extends beyond the pulmonary arteries and into the cerebellum
Pulmonary arterial hypertension is no longer confined to the pulmonary circulation in this analysis. Structural and functional brain imaging tied PAH to reduced cerebellar white matter volume, thinner frontal gyri, and weaker cerebellar-frontal connectivity, with parallel declines in executive function and processing speed. The pattern was striking because it appeared in PAH, but not in other heart or lung diseases used for comparison. In practical terms, a disease long approached as a cardiopulmonary disorder now carries a measurable neurologic footprint.
The clinical consequence is not subtle. The affected circuit linked the left cerebellum to the left superior frontal gyrus, a pathway central to coordination between motor planning, attention, working memory, and higher-order judgment. When that axis falters, the bedside phenotype can look like slowed thinking, difficulty shifting between tasks, weaker abstract reasoning, and reduced problem-solving capacity. The imaging phenotype and the cognitive phenotype moved together rather than appearing as unrelated findings.
Imaging abnormalities tracked with executive dysfunction
UK Biobank data provided the large-scale signal, and a prospective validation cohort strengthened it. Across those cohorts, patients with pulmonary hypertension showed a reproducible set of abnormalities: cerebellar white matter loss, thinner frontal gyri, and impaired cerebellar-frontal connectivity. These were not generic signs of global illness. They pointed to a specific network injury centered on the cerebellar-frontal axis.
That specificity matters because the simplest explanation, reduced cerebral perfusion from advanced cardiopulmonary disease, does not adequately account for the findings. Similar neurologic deficits were not seen across related cardiac or pulmonary conditions. The investigators therefore pursued a different mechanism: a shared inflammatory and lysosomal injury program affecting both lung vasculature and brain tissue. The cerebellum, often overlooked in cardiopulmonary disease, emerged as an organ vulnerable to the same biologic forces that drive pulmonary vascular remodeling.
Inflammation and lysosomal dysfunction provide a mechanistic bridge
A central clue came from plasma proteomics and genomics. Olink profiling linked inflammatory circulating proteins to the brain abnormalities, while a NCOA7 single nucleotide polymorphism, rs11154337, tracked with the imaging and clinical phenotype in PAH. The variant associated with improved cerebellar-frontal connectivity, pointing to a protective role for higher NCOA7 activity. In a disease defined by vascular inflammation, that kind of association is biologically plausible rather than decorative.
NCOA7 helps regulate lysosomal lipid handling by supporting vacuolar ATPase function and maintaining the acidic compartment needed for lipid and protein degradation. When that system fails, lysosomes become less efficient, lipids accumulate, oxysterols rise, and inflammatory signaling intensifies. In pulmonary artery endothelial cells, that mechanism is already tied to pulmonary vascular disease. The new work extends the same logic to the brain, where microglia appear to participate in the same dysfunctional inflammatory loop.
The biology is important because it explains how a vascular disease can become a neurodegenerative problem without relying on a single catastrophic event. Chronic lysosomal stress can gradually reshape cell behavior, amplify inflammatory signaling, and damage white matter integrity. In other words, the brain injury in PAH looks less like an isolated accident and more like the downstream consequence of a persistent molecular defect.
Microglial activation and white matter injury converged in the PAH brain
Brain tissue from PAH showed increased microglial activation and white matter derangement. That pairing is meaningful. Microglia are not passive bystanders; they are resident immune cells that survey the local microenvironment, clear debris, and respond rapidly to injury. When their lysosomal machinery is disturbed, they can shift from repair-oriented behavior toward a more inflammatory state that undermines myelin integrity and neural network stability.
Mouse experiments tightened the link. In the PAH model, cerebellar degeneration occurred and worsened further with Ncoa7 deficiency. Cerebellar NCOA7 expression increased in both human and mouse PAH, suggesting a compensatory response to stress. Loss of that response served as a second hit, amplifying oxysterol generation, lysosomal alkalinization, and inflammatory injury. The experimental design did not prove every step in humans, but it aligned the clinical phenotype with a coherent pathobiologic sequence.
Why the cerebellum matters in a cardiopulmonary disease
The cerebellum is often associated with coordination, yet its connections to frontal cortex make it integral to executive function and cognitive speed. Injury to this network can produce a quieter but clinically consequential syndrome: slower processing, less efficient working memory, and more difficulty with complex planning. For patients with PAH, these deficits may affect medication management, adherence, symptom reporting, and the ability to navigate a high-burden chronic illness.
The study therefore changes how PAH should be viewed at the bedside. A patient with exertional dyspnea and right-heart strain may also carry a neurocognitive burden that is not visible on routine examination. The absence of obvious neurologic symptoms would not exclude cerebellar-frontal dysfunction, especially when the impairment is dominated by speed and executive control rather than focal deficits.
NCOA7-linked inflammation now looks like a therapeutic target
The most important advance is conceptual, but it is not merely theoretical. By tying NCOA7, lysosomal dysfunction, inflammatory plasma proteins, microglial activation, and cerebellar-frontal impairment into one chain, the work creates a candidate mechanism for intervention. It also widens the therapeutic horizon beyond pulmonary vasodilation and vascular remodeling alone.
A treatment strategy built around this biology would likely need to do more than lower pulmonary pressures. It would need to reduce lysosomal stress, blunt oxysterol generation, and quiet microglial inflammation if the goal is to preserve cognition and brain structure. The data do not identify a therapy, yet they do define a tractable molecular axis for future drug development and biomarker work.
The unanswered clinical issue is how early these brain changes begin and whether they can be prevented before measurable network injury develops. Another open question is whether cognitive screening should become routine in PAH clinics, especially in patients with severe disease or evidence of inflammatory activation. The current study does not settle those questions, but it makes clear that PAH can no longer be treated as a disease of the lungs alone.